USP Ephedra Review Scheduled For July; RAND Report Slated For Early Fall
This article was originally published in The Tan Sheet
Executive Summary
The U.S. Pharmacopeia will discuss standard-setting issues related to the supplement ingredient ephedra during an internal meeting July 17
You may also be interested in...
Metabolife Federal Probe Spurs Release Of Ephedrine Complaint Records
An FDA task force will review the 13,000 ephedrine alkaloid patient complaint records Metabolife is releasing in response to publicity surrounding a criminal investigation into whether the company lied about its knowledge of adverse events
Metabolife Federal Probe Spurs Release Of Ephedrine Complaint Records
An FDA task force will review the 13,000 ephedrine alkaloid patient complaint records Metabolife is releasing in response to publicity surrounding a criminal investigation into whether the company lied about its knowledge of adverse events
Metabolife Federal Probe Spurs Release Of Ephedrine Complaint Records
An FDA task force will review the 13,000 ephedrine alkaloid patient complaint records Metabolife is releasing in response to publicity surrounding a criminal investigation into whether the company lied about its knowledge of adverse events